CMPS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Compass Pathways (CMPS) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available. The stock has strong positive catalysts, including successful Phase 3 trial results for its COMP360 treatment, multiple analyst upgrades with increased price targets, and significant hedge fund buying activity. While the technical indicators are currently neutral to bearish, the long-term growth potential outweighs short-term volatility.
The MACD is negatively expanding, indicating bearish momentum. RSI is at 36.052, suggesting the stock is approaching oversold territory but is still neutral. Moving averages are converging, showing no clear trend. Key support is at 6.739, and resistance is at 8.134. Overall, the technical indicators show a neutral to bearish trend in the short term.
Successful Phase 3 trial results for COMP360, meeting primary endpoints with statistical significance.
Analysts have raised price targets significantly, with the highest at $22, citing strong efficacy and safety profile for COMP
Hedge fund buying activity has increased by 302.54% over the last quarter, indicating institutional confidence.
The stock experienced a 3.90% decline in the regular market session, and pre-market data shows a further 1.42% drop, indicating short-term bearish sentiment.
No recent news or valuation data is available to provide additional clarity.
In Q3 2025, revenue remained at $0, but net income improved significantly, up 257.69% YoY to -$137.7M. EPS also improved by 157.14% YoY to -1.44. While the company is not yet profitable, the financials show progress in reducing losses.
Analysts are overwhelmingly positive, with multiple upgrades and increased price targets ranging from $15 to $22. Analysts highlight the potential FDA approval of COMP360 as a major growth driver, with a $1.5B peak sales opportunity for treatment-resistant depression.
